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Abstract
Introduction The prevalence of polymorphisms among
the metabolising enzymes and pharmacodynamic receptors
relevant for the thiazolidinediones differs by ethnic group,
a factor that may modify risk of adverse drug events.
Objective The aim of the study was to determine if the
risk of oedema or heart failure associated with the thiazo-
lidinediones varies in populations in Australia, Canada,
Hong Kong, Japan, Korea and Taiwan.
Methods Sequence symmetry analyses were undertaken
to investigate the risk of peripheral oedema, as measured
by incident furosemide dispensing, and risk of hospitali-
sations for heart failure. Results were pooled, with Aus-
tralia and Canada representing predominantly Caucasian
population and all other countries contributing to Asian
population estimates.
Results Pooled estimates of risk for furosemide initiation
in the Caucasian populations were significantly increased
for pioglitazone [adjusted sequence ratio (ASR) 1.47; 95 %
confidence interval (CI) 1.14–1.91] and rosiglitazone (ASR
1.65; 95 % CI 1.58–1.72), while in the Asian populations,
the pooled risk estimates were lower (ASR 1.11; 95 % CI
0.93–1.32 and ASR 1.21; 95 % CI 1.01–1.45 for pioglita-
zone and rosiglitazone, respectively). Results for
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Key Points
No increased risk of either peripheral oedema or
heart failure hospitalisation was found for
pioglitazone in the Asian population, while, in the
predominantly Caucasian population, pioglitazone
was associated with a 47 % increased risk of oedema
and an 88 % increased risk of hospitalisation for
heart failure.
The risk of oedema and heart failure associated with
rosiglitazone was generally lower in the Asian
population than in the Caucasian population.
Our results highlight the need for regulatory agencies
to consider differences in response to medicines by
ethnicity and for more research to determine the
incidence of adverse events across ethnic groups.
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hospitalisation for heart failure showed a similar trend,
with elevated risk in the Australian data (ASR 1.88; 95 %
CI 1.01–3.5 and ASR 1.25; 95 % CI 0.76–2.05 for
pioglitazone and rosiglitazone, respectively), while no
increased risk was found in the pooled results for the Asian
populations.
Conclusion The risk of both oedema and heart failure
with thiazolidinediones was higher in predominantly Cau-
casian countries than in the Asian countries assessed.
Assessment of adverse events by ethnicity may support
safer medicine use.
1 Introduction
Meta-analytic evidence from randomised controlled trials
shows that the thiazolidinediones rosiglitazone and
pioglitazone are associated with heart failure and oedema
[1–3]. Rosiglitazone appears to have a higher risk of heart
failure than pioglitazone [4, 5]. A meta-analysis of com-
parative, observational studies (12 cohort studies and four
case–control studies) found a 22 % [pooled odds ratio 1.22;
95 % confidence interval (CI) 1.14–1.31] increased risk for
heart failure with rosiglitazone compared with pioglitazone
on the basis of data from eight studies [5]. Another meta-
analysis, limited to cohort studies only, reported similar
results [4]. In both meta-analyses, all but one of the
included studies were undertaken in the USA, Canada or
the UK, with the remaining study from Taiwan [4, 5].
It is important to assess the safety of the thiazolidine-
diones across all ethnic groups as there is the potential for
the adverse event profile to differ. In vitro studies show
pioglitazone is metabolized by the polymorphic enzymes
CYP2C8 and to a lesser extent CYP3A4 [6], while
rosiglitazone is metabolised by CYP2C9 and CYP2C8 [7].
The prevalence of CYP2C8 genotypes varies across ethnic
groups, with one report finding a CYP2C8*3 allele fre-
quency of 9 % in Caucasians and 2 % in Asians [8] and
another showing up to 17 % in Southern European popu-
lations and none in the Japanese population [9]. A novel
CYP2C8 variant, CYP2C8*11 was not found in Caucasians
or African Americans, but was found in up to 1 % of
Vietnamese [10]. CYP2C8*11 was found to increase
clearance of rosiglitazone [10]. The presence of the
CYP2C8*3 allele has also been shown to increase the
clearance of rosiglitazone [11] and pioglitazone [12] and to
affect glycaemic control [13]. Reactive metabolites of the
thiazolidinediones have been linked to liver toxicity [14],
and so may have the potential to influence other adverse
events; however, we located no publications reporting their
contribution to adverse cardiac events.
The prevalence of the CYP2C9 genotype also varies
across ethnic groups, with CYP2C9*1 present in 60 % in
the Caucasian population compared with 93 % in the
Japanese, 92 % in the Chinese, 91 % in the Korean and
91 % in other Asian populations [15]. CYP2C9*2 is pre-
sent in up to 19 % of Caucasian populations; however, it is
virtually non-existent in East Asian populations [9].
CYP2C9*3 variants are also more common in Caucasian
populations than in East Asian populations [9]. These large
variations might have the potential to impact on the
metabolism and effect of rosiglitazone.
Further, there is the potential for pharmacodynamic-
based variation in response to the thiazolidinediones across
ethnic groups. Thiazolidinediones are thought to exert their
action by binding to peroxisome proliferator-activated
receptor-gamma [16]. This receptor also has variants, with
the Pro 12Ala polymorphism thought to reduce transcrip-
tional activity [17]. This polymorphism has been shown to
affect risk of type 2 diabetes, glucose control and lipid
profiles [18–20]. Variation in the prevalence of this poly-
morphism occurs across ethnic groups, with a prevalence
of 4 % in the Japanese population [19] and 14 % in the
Danish population [18]. Another gene, the adiponectin
(ADIPOQ), has also been reported to be associated with
thiazolidinediones response. Treated with pioglitazone,
type 2 diabetes mellitus (T2DM) patients with the ADI-
POQ C-11377 CC genotype were associated with a sig-
nificantly smaller reduction in glycated haemoglobin
(HbA1c) compared with the minor G allele carriers [21]. In
rosiglitazone therapy, ADIPOQ C-11377 CC genotype
T2DM patients had a greater reduction in fasting plasma
glucose compared with the CG and GG genotypes carriers
[22].
Collectively, these polymorphic variations, which vary
in prevalence across ethnic groups, affect both pharma-
cokinetic and pharmacodynamic responses to the thiazo-
lidinediones and have been shown to affect hypoglycaemic
response to the medicines. The variations may also affect
the prevalence of adverse events across populations;
however, this has not been the focus of studies to date.
Given the ongoing concerns about risk of heart failure and
oedema with the thiazolidinediones, the purpose of this
study was to determine if the risk of heart failure and
oedema associated with the thiazolidinediones (i.e.
rosiglitazone and pioglitazone) varied between populations
located in Asia, Australia and Canada.
2 Methods
In order to study whether the risk of heart failure and
oedema with thiazolidinediones differed between ethnic
groups, we performed a study among member groups of the
Asian PharmacoEpidemiology Network (AsPEN) [23].
AsPEN provides a mechanism to support the conduct of
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cross-country pharmacoepidemiologic research to facilitate
prompt detection and communication of emerging safety
issues between countries. The AsPEN participants in this
study were based in Australia, Hong Kong, Japan, Korea and
Taiwan. The datasets included the Australian Government
Department of Veterans’ Affairs healthcare claims database
(Australia) (2005–2010), the Australian Government Drug
Utilisation Subcommittee dataset (2005–2009), the Clinical
Data Analysis and Reporting System (Hong Kong)
(2008–2012), the Japan Medical Data Centre insurance
claims database (2005–2010), the Hamamatsu Medical
University Database (Japan) (1999–2010), the Korea Health
Insurance Review and Assessment Service database (HIRA
DB) (Korea) (2006–2008), and the National Health Insur-
ance Research Database (Taiwan) (2002–2008). The Aus-
tralian dataset contains prescription and hospital claims
records for all veterans and their dependents in Australia
(approximately 300,000) and represents a predominantly
elderly cohort. The Hong Kong dataset is a national elec-
tronic healthcare record of public hospitals and their
ambulatory clinics, covering over 7 million persons. The
Japanese dataset represents a privately insured population of
approximately 300,000; an adult working population and
their dependents. The Hamamatsu Medical University
Database is a hospital records database covering approxi-
mately 200,000 persons. The Korean data are from the
national insurance data and include the entire population of
approximately 50 million persons. The Taiwanese dataset is
also a national insurance dataset covering 23 million per-
sons, and a random sample of 1 million persons was
included in this study [23]. All these datasets encompass
patient-level dispensing data, which include the following: a
patient identifier, patient demographics, date of medicine
supply, medicine dispensed, quantity and strength. Medici-
nes are mapped from individual country-specific codes to
the WHO Anatomical Therapeutic Chemical (ATC) classi-
fication codes [24]. Patient-level hospital datasets are also
available, which include a patient identifier, patient demo-
graphics, date of admission and discharge, primary diag-
noses, secondary diagnoses, and procedures undertaken
during admission. Diagnoses are coded according to the
International Classification of Diseases (ICD) 9th or 10th
edition [25]. In addition to these datasets, we also used the
national prescription dispensing dataset from Australia. This
patient-level dataset includes all prescriptions reimbursed
under Australia’s national health insurance for pharmaceu-
ticals and covers a population of 23 million persons. The
Canadian Institute for Health Information (CIHI)’s National
Prescription Drug Utilization Information System (NPDUIS)
(2000–2012) was used to enable comparisons between
Australia and Canada, countries thought to have populations
of similar ethnic mix. NPDUIS contains public drug claims
data from seven jurisdictions in Canada. Patient-linked
hospital datasets at the national level were not available for
inclusion in the analyses for Australia or Canada.
We used sequence symmetry analysis (SSA), a signal
detection method for adverse drug events utilising admin-
istrative claims data [26], to assess the association between
the thiazolidinediones and oedema or heart failure across
countries. The method has been validated against adverse
events identified in randomised controlled trials and against
negative controls from product information of unrelated
products [27]. The method has also been validated in a
simulation study [28]. The method has been shown to have
a similar performance to signal detection methods used
with spontaneous adverse drug reaction reports [29], and
the method has been shown to provide timely signals for
cardiovascular events with the thiazolidinediones [30]. The
AsPEN initiative works on a distributive network model
[31] that requires participants to create a common mini-
mum dataset including (1) a unique patient identifier; (2) a
variable to identify the medicine dispensed based on the
WHO standard ATC code; and (3) a variable to identify the
date of medicine supply; and when using hospital datasets
(4) a variable to identify the date of admission and (5) a
variable to identify the primary diagnosis of interest based
on the ICD code. The co-ordinating centre for this study,
the University of South Australia, developed the statistical
analysis code as a stand-alone SAS program for execution
by each participant in their home institution. The SAS
program used global macro variables, which required
participants to enter the variable names used in their
datasets rather than forcing the creation of a data file with
common data variable names. This approach eliminates a
complex programming burden for participants and over-
comes barriers due to language and disparate data struc-
tures. Participants executed the SAS code, and a
standardised file of summary results was returned to the co-
ordinating centre for collation. These standardised files
included graphics of the number of people dispensed the
study medicines each month (prevalent population), the
number of people starting study medicines each month
(incident population), and the results of the SSA, including
the graphics showing temporal sequences.
Pioglitazone and rosiglitazone were available in all
countries with the exception of Japan, where rosiglitazone
only was available. Outcomes assessed were:
1. The first dispensing of furosemide (ATC code
C03CA01) as an indicator medicine for oedema
(furosemide is also used in exacerbations of heart
failure).
2. The first hospital admission with a primary diagnosis
of heart failure (ICD 10 codes I50 or ICD 9 code 428)
as the indicator of heart failure, where hospital data
were available.
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We also included analyses for each outcome with met-
formin (ATC code A10BA02). Metformin served as a
marker of the background rate of cardiovascular adverse
events associated with initiation of medicines for diabetes,
as some people will have established cardiovascular dis-
ease at the time of first commencing therapy for diabetes.
In the SSA method, the dates of incident dispensing of
rosiglitazone, pioglitazone, metformin, and furosemide and
hospitalisation for heart failure were determined for each
individual patient. All incident dispensings that occurred
within 1 year of each other for the same person were
included in the analysis. We excluded patients who initi-
ated any of the study medicines in the first year of data
coverage in any dataset to ensure we limited the analyses to
incident users. The crude sequence ratio (SR) was calcu-
lated by dividing the number of persons with furosemide
initiated after rosiglitazone initiation with the number of
persons with furosemide initiated prior to rosiglitazone.
The SR estimates the incidence rate ratio of the event in
exposed compared with non-exposed person-time. The
SSA method uses a within-person design, making it robust
towards confounders that are stable over time [26]; how-
ever, it is sensitive to prescribing trends over time.
Therefore, a null-effect SR was calculated to adjust for
temporal trends. The null-effect SR is the expected SR in
the absence of a causal association, given the incident
medicine use and events in the background population. A
description of the formula used for this value is provided
elsewhere [32]. An adjusted SR was obtained by dividing
the crude SR by the null-effect SR, and 95 % CIs were
calculated [32]. The same analyses were undertaken for the
other medicines and the hospitalisation outcome. The SSAs
were restricted to sequences of incident dispensings or
sequences of dispensings and hospitalisations within
12 months of each other to limit the effect of age and other
potential time-varying covariates on the probability of
exposure and outcome. Moreover, a 12-month period has
better specificity and positive predictive value compared
with shorter periods [27]. Results were pooled according to
countries predominant ethnic mix; thus Japan, Hong Kong,
Korea and Taiwan were pooled for the Asian cohort, with
Canada and Australia contributing to the Caucasian cohort.
Pooled estimates were obtained with a random effect
model, using the generic inverse variance method [33].
3 Results
3.1 Oedema
With regards to the oedema outcome, there were significant
associations between incident rosiglitazone use and inci-
dent furosemide dispensing in Australia and Canada, with
the pooled Australia–Canada estimate also significant
[adjusted sequence ratio (ASR) 1.65; 95 % CI 1.58–1.72]
(Fig. 1). Korea and Taiwan had similar point estimates,
with only the result in Korea reaching statistical signifi-
cance. These risk estimates were lower than Australia–
Canada results (Fig. 1). There was a significant elevated
risk in Hong Kong, which was of greater magnitude than
the risk identified in the predominantly Caucasian popu-
lations. The pooled estimate for the Asian population was
significant (ASR 1.21; 95 % CI 1.01–1.45), but the mag-
nitude of the estimate was lower than the predominantly
Caucasian population result.
For incident pioglitazone use, there was a significant
association with incident furosemide dispensings within
each predominantly Caucasian country and when the
results were pooled (ASR 1.47; 95 % CI 1.14–1.91)
(Fig. 2). In Japan, Korea and Taiwan, there was no sig-
nificant association; however, results in Hong Kong were
elevated. The pooled Asian population estimate was not
significant (ASR 1.11; 95 % CI 0.93–1.32).
For incident metformin use, there was a significant
association between metformin and incident furosemide
dispensing in the pooled predominantly Caucasian popula-
tion (ASR 1.26; 95 % CI 1.05–1.50) (Fig. 3); however, this
was lower than the pioglitazone and rosiglitazone estimates.
No significant association was found for metformin in the
pooled Asian population (ASR 1.08; 95 % CI 0.95–1.22).
3.2 Heart Failure
The risk of hospitalisation for heart failure after rosiglita-
zone initiation was not significant in the Australian veteran
population (ASR 1.25; 95 % CI 0.76–2.05). For pioglita-
zone, there was a significant association with heart failure
hospitalisation (ASR 1.88; 95 % CI 1.01–3.5). There was
no association between metformin use and hospitalisation
for heart failure (ASR 1.11; 95 % CI 0.89–1.38).
No significant risk was observed for rosiglitazone use
and heart failure hospitalisation in Taiwan; however, a
significantly elevated risk was observed in Hong Kong
(ASR 5.16; 95 % CI 1.53–17.35) and a slightly elevated
risk in Korea (ASR 1.20; 95 % CI 1.01–1.42) (Fig. 4). The
estimate for rosiglitazone and risk of hospitalisation for
heart failure in the pooled Asian population was not sig-
nificant (ASR 1.24; 95 % CI 0.84–1.83). For pioglitazone
there were no significant associations in Japan, Korea or
Taiwan, but there was for an increase in Hong Kong. No
significant association was found when results were pooled
(ASR 1.06; 95 % CI 0.79–1.43) (Fig. 4). No significant
association was found in any Asian country or in the
pooled analysis between metformin and heart failure hos-
pitalisation (ASR 0.96; 95 % CI 0.89–1.04) (Fig. 4).
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4 Discussion
This is the first study to examine variation in the risk of
oedema and heart failure associated with the thiazolidine-
diones by ethnic population. We found elevated risk for
oedema, as indicated by furosemide dispensings, in the
Australian and Canadian populations for both pioglitazone
and rosiglitazone, results which are consistent with meta-
analytic results from randomised controlled trials [1]. By
contrast, we found no elevated risk of oedema with
pioglitazone in Korea, Taiwan or Japan, although the risk
was elevated in the Hong Kong population. Results for
rosiglitazone were elevated when estimates for the Asian
population were pooled, but were lower than the pooled
estimates for the Australian and Canadian populations for
the same medicine.
With regard to the risk of hospitalisation for heart fail-
ure, we only found elevated risk with rosiglitazone and
Fig. 2 Sequence symmetry
analysis results for incident
pioglitazone use and risk of
incident furosemide use. Aust
(DVA) Australian Government
Department of Veterans’ Affairs
healthcare claims database,
Australia Australian
Government Drug Utilisation
Subcommittee dataset, CI
confidence interval, Japan I
Japan Medical Data Centre
insurance claims database,
Japan II Hamamatsu Medical
University Database, IV inverse
variance, SE standard error
Fig. 1 Sequence symmetry
analysis results for incident
rosiglitazone use and risk of
incident furosemide use. Aust
(DVA) Australian Government
Department of Veterans’ Affairs
healthcare claims database,
Australia Australian
Government Drug Utilisation
Subcommittee dataset, CI
confidence interval, IV inverse
variance, SE standard error
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pioglitazone in the Hong Kong population, rosiglitazone in
Korea and pioglitazone in the Australian veteran popula-
tion. The limited sample size in Australia is likely to have
reduced the study power for this endpoint for rosiglitazone.
No significant risk of heart failure was found with piogli-
tazone in Korea, where a large sample size was available.
We used metformin and risk of dispensing for fur-
osemide or a hospitalisation with a primary diagnosis of
heart failure as indicators of the background rate of oedema
and heart failure associated with diabetes diagnosis. We
found that in the Australian and Canadian populations, the
risk of oedema was higher with the thiazolidinediones
compared with metformin; however, CIs did overlap. In the
Asian populations, the risk of oedema with rosiglitazone
was higher than that with metformin, while pioglitazone
and metformin results were similar. The risk of hospitali-
sation for heart failure was similar among all three diabetes
medicines for Korea and Taiwan, but elevated in Hong
Kong for the thiazolidinediones compared with metformin.
The underlying reason for the elevated risks of oedema and
heart failure hospitalisation in Hong Kong is unclear; it
may be that there are different treatment pathways in Hong
Kong compared with the other Asian countries that influ-
ence these results.
The risk estimates in our study for oedema were higher
for rosiglitazone than pioglitazone; by comparison, a
published meta-analysis reported similar risk estimates
between the two thiazolidinediones [1].
While not conclusive, our results are suggestive of a
potential difference in risk of adverse events across coun-
tries, with slightly lower estimates in most Asian countries,
with the exception of Hong Kong, compared with Australia
and Canada. Differences in the underlying prevalence of
polymorphisms in both metabolising enzymes and phar-
macodynamic receptors may have played a role; however,
differences in other factors, including diet, physical activity
or healthcare practice may also be contributors.
Our results highlight the need for regulatory agencies to
consider differences in response to medicines by ethnic
group and for more research to determine the incidence of
adverse events across ethnic groups. Rosiglitazone was
withdrawn from the European market in 2010 because of
its adverse effect profile and has also been withdrawn from
India, New Zealand, Hong Kong and South Africa; how-
ever, it is still available in Australia, the USA, Korea and
Taiwan. If more research was undertaken to shed light on
how adverse events varied by ethnicity, it may be that more
nuanced regulatory responses, rather than whole-of-country
withdrawal, could be developed.
Our research study has several strengths, including the
large populations under study. The total population from
Australia and Canada was over 46 million; the total pop-
ulation from the Asian countries was over 80 million. We
used standardised code and standardised data variables to
avoid differences due to coding. We also used metformin
as a marker of the background rate of adverse events
associated with diabetes and medicine initiation. Limita-
tions of our study include a lack of diagnostic information
at the outpatient level in the majority of countries, and
hence the reliance on furosemide as the proxy indicator for
oedema. Furosemide is also used for the management of
exacerbation of heart failure. Given both outcomes are
Fig. 3 Sequence symmetry
analysis results for incident
metformin use and risk of
incident furosemide use. Aust
(DVA) Australian Government
Department of Veterans’ Affairs
healthcare claims database, CI
confidence interval, Japan I
Japan Medical Data Centre
insurance claims database,
Japan II Hamamatsu Medical
University Database, IV inverse
variance, SE standard error
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adverse events of the medicines of interest and the risk of
each adverse event is likely to be proportional, this limi-
tation should not affect the comparisons between countries.
A second limitation is the lack of large datasets for the
hospitalisation outcome in Canada and Australia, limiting
the strength of conclusions that could be drawn regarding
the more serious outcome of heart failure hospitalisation. A
third limitation is the differences in medications available
in each country, resulting in the exclusion of some com-
parisons. A further limitation is that ethnic data were not
Fig. 4 Sequence symmetry
analysis results for incident
diabetes medicine use and risk
of incident heart failure
hospitalisation: Asian countries.
CI confidence interval, Japan I
Japan Medical Data Centre
insurance claims database, IV
inverse variance, SE standard
error
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available, leading to a potential misclassification bias
where the non-Caucasian population in Australia and
Canada was pooled in the Caucasian population. The ethnic
information, therefore, needs to be documented in health-
care claims datasets to facilitate the assessment of ethnic
differences. Finally, we cannot exclude the possibility that
some of the differences observed across countries may be
due to differences in healthcare practice. However, the
consistency of results in Japan, Korea and Taiwan suggests
this impact, if real, is unlikely to be large.
5 Conclusion
Our multi-national study to assess differences in adverse
events across the Asian and predominantly Caucasian ethnic
populations is suggestive of differences in the incidence of
oedema and heart failure by ethnic group, with risk esti-
mates generally being lower in the Asian populations. While
differences in environmental factors, including diet, physical
activity or healthcare practice, may also be contributors,
greater consideration to quantifying adverse events by ethnic
group as part of regulatory assessment and post-marketing
surveillance assessment is required.
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